Exelixis, Inc. $EXEL Shares Acquired by Assenagon Asset Management S.A.

Key Points

• Assenagon Asset Management increased its Exelixis stake by 212.7% in the second quarter, purchasing 291,593 additional shares. Institutional investors collectively own approximately 85.27% of EXEL.
• Exelixis reported quarterly EPS of $0.91, beating the $0.85 consensus, while revenue rose 10.6% year over year to $628.7 million, slightly below estimates.
• Analyst sentiment remains mixed: Exelixis has a consensus “Hold” rating and a $49.79 price target, while recent insider transactions show executives and a director selling shares.

Assenagon Asset Management S.A. lifted its position in Exelixis, Inc. (NASDAQ:EXEL - Free Report) by 212.7% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 428,673 shares of the biotechnology company's stock after purchasing an additional 291,593 shares during the period. Assenagon Asset Management S.A. owned about 0.17% of Exelixis worth $23,324,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in EXEL. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in shares of Exelixis by 81.6% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 43,181 shares of the biotechnology company's stock worth $1,592,000 after acquiring an additional 19,407 shares in the last quarter. Goldman Sachs Group Inc. increased its stake in shares of Exelixis by 4.9% in the 1st quarter. Goldman Sachs Group Inc. now owns 1,466,779 shares of the biotechnology company's stock valued at $54,153,000 after purchasing an additional 68,133 shares in the last quarter. Focus Partners Wealth raised its holdings in Exelixis by 83.4% in the 1st quarter. Focus Partners Wealth now owns 38,458 shares of the biotechnology company's stock worth $1,420,000 after purchasing an additional 17,483 shares during the period. Geneos Wealth Management Inc. increased its position in shares of Exelixis by 134.3% in the first quarter. Geneos Wealth Management Inc. now owns 1,647 shares of the biotechnology company's stock valued at $61,000 after buying an additional 944 shares in the last quarter. Finally, Sivia Capital Partners LLC raised its stake in shares of Exelixis by 23.8% during the 2nd quarter. Sivia Capital Partners LLC now owns 14,362 shares of the biotechnology company's stock worth $633,000 after buying an additional 2,764 shares during the period. Hedge funds and other institutional investors own 85.27% of the company's stock.

Exelixis Price Performance

EXEL stock opened at $54.07 on Monday. The business has a fifty day moving average of $54.17 and a two-hundred day moving average of $47.97. The stock has a market cap of $13.59 billion, a price-to-earnings ratio of 17.00, a price-to-earnings-growth ratio of 1.63 and a beta of 0.44. Exelixis, Inc. has a 52-week low of $33.76 and a 52-week high of $57.57.

Exelixis (NASDAQ:EXEL - Get Free Report) last announced its quarterly earnings results on Wednesday, August 5th. The biotechnology company reported $0.91 EPS for the quarter, beating the consensus estimate of $0.85 by $0.06. The business had revenue of $628.69 million for the quarter, compared to analyst estimates of $636.40 million. Exelixis had a return on equity of 42.17% and a net margin of 35.33%.The company's quarterly revenue was up 10.6% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.75 EPS. As a group, sell-side analysts anticipate that Exelixis, Inc. will post 3.15 EPS for the current year.

Insider Transactions at Exelixis

In related news, Director Sue Gail Eckhardt sold 9,812 shares of the stock in a transaction on Monday, June 1st. The shares were sold at an average price of $50.14, for a total transaction of $491,973.68. Following the completion of the sale, the director owned 16,079 shares in the company, valued at $806,201.06. This represents a 37.90% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Christopher J. Senner sold 34,901 shares of the stock in a transaction dated Monday, May 18th. The stock was sold at an average price of $50.00, for a total transaction of $1,745,050.00. Following the sale, the chief financial officer owned 952,317 shares of the company's stock, valued at $47,615,850. This trade represents a 3.54% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders have sold 130,824 shares of company stock valued at $6,555,231. 2.60% of the stock is owned by corporate insiders.

Analyst Ratings Changes

A number of brokerages have recently issued reports on EXEL. Weiss Ratings lowered Exelixis from a "buy (b+)" rating to a "buy (b)" rating in a research note on Friday, July 24th. Wells Fargo & Company upped their target price on shares of Exelixis from $40.00 to $49.00 and gave the stock an "equal weight" rating in a report on Monday, July 13th. Stifel Nicolaus increased their target price on shares of Exelixis from $47.00 to $51.00 and gave the company a "hold" rating in a research report on Thursday. Wall Street Zen lowered shares of Exelixis from a "strong-buy" rating to a "buy" rating in a research report on Saturday. Finally, Citizens Jmp upped their price objective on shares of Exelixis from $50.00 to $55.00 and gave the company a "market outperform" rating in a research note on Wednesday, June 24th. Seven research analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat, Exelixis currently has a consensus rating of "Hold" and a consensus price target of $49.79.

Exelixis News Roundup

Here are the key news stories impacting Exelixis this week:

• Positive Sentiment: Exelixis reported second-quarter EPS of $0.91, ahead of the $0.85-$0.86 analyst consensus and up from $0.75 a year earlier. Revenue rose 10.6% year over year to approximately $628.7 million, while the company continues to benefit from its established cabozantinib business. Exelixis Q2 earnings
• Positive Sentiment: The company launched a new Phase 3 trial testing zanzalintinib in residual colorectal cancer, expanding the potential market for its pipeline and providing another long-term growth catalyst. Exelixis colorectal cancer trial
• Positive Sentiment: TD Cowen reaffirmed a Buy rating and a $55 price target, citing resilience in cabozantinib, cost discipline and upside from zanzalintinib despite near-term guidance pressure.
• Neutral Sentiment: Stifel raised its price target from $47 to $51 but retained a Hold rating. Its target remains below the recent trading level, suggesting limited near-term upside in the analyst’s view.
• Negative Sentiment: Exelixis lowered the midpoint of its 2026 revenue outlook by $50 million, primarily because the NET launch has been slower than expected. Although the EPS beat was encouraging, the revenue miss and reduced outlook are weighing on growth expectations. Exelixis 2026 guidance
• Negative Sentiment: Leerink Partners downgraded EXEL from Outperform to Market Perform and set a $52 price target, below the recent share price. Leerink Partners downgrade
• Negative Sentiment: Zacks Research maintains a Strong Sell rating and made small reductions to its FY2026-FY2028 EPS forecasts, including a FY2026 estimate of $3.12 versus the broader consensus of $3.15.

Exelixis Company Profile

Exelixis, Inc is a biotechnology company specializing in the discovery, development and commercialization of small molecule therapies primarily for the treatment of cancer. Building on a platform that leverages model organism genetics and high-throughput screening, the company focuses its research on kinase inhibitors that modulate critical signaling pathways involved in tumor growth and metastasis. Exelixis's translational research approach aims to advance novel compounds from early-stage discovery through clinical development and regulatory approval.

The company's most recognized products include CABOMETYX® (cabozantinib), approved for the treatment of advanced renal cell carcinoma and hepatocellular carcinoma, and COMETRIQ® (cabozantinib) for metastatic medullary thyroid cancer.

Want to see what other hedge funds are holding EXEL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Exelixis, Inc. (NASDAQ:EXEL - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source